Cancer immunotherapy has recently made progress by focusing on overcoming T‐cell regulatory checkpoints with blocking monoclonal antibodies directed against cytotoxic T‐lymphocyte associated protein‐4 or programmed cell death 1/programmed cell death ligand 1 (PD‐1/PD‐L1) 2. Here, CD274 is linked to cancer.